TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

LEARNING OBJECTIVES

• Consider research data, clinical investigator perspectives and available guideline recommendations to individualize therapy for patients with localized or advanced breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers in the newly diagnosed or relapsed/refractory settings.
• Recognize oncogenic pathways mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these pathways.
• Develop a long-term care plan for patients with diverse hematologic cancers and solid tumors, considering age, performance status, tumor-specific biomarker profile, prior exposure to systemic therapy, symptomatology and personal goals of treatment.
• Discuss the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals or presented at major oncology conferences.
• Recall clinical trial data with FDA-approved and investigational agents for patients with localized, locally advanced or metastatic breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and, as applicable, refer eligible patients for clinical trial participation.
• Appraise the common and rare side effects associated with approved and investigational therapeutic agents for cancer, and use this information to develop supportive management plans for patients.
• Apply clinical research findings in the determination of best-practice selection and sequencing of available treatment modalities for patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
• Recognize the mechanisms of action, efficacy and safety of approved and investigational therapies to determine the current and potential utility of those agents in clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Thomas A Abrams, MD
Senior Physician
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Director, Liver Tumor Center
Boston, Massachusetts

Advisory Committee: Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Servier; Ownership Interest: Biogen, Guardant Health, Jounce Therapeutics.

John N Allan, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Advisory Committee: AbbVie Inc, Ascentage Pharma, Epizyme, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC; Consulting Agreement: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Janssen Biotech Inc, Pharmacyclics LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc.

Deborah K Armstrong, MD
Professor of Oncology
Professor of Gynecology and Obstetrics
Skip Viragh Outpatient Cancer Building
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Advisory Committee: AbbVie Inc, Cue Biopharma, Eisai Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Pfizer Inc, Syndax Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

Arjun Balar, MD
Associate Professor, Department of Medicine
Director, Genitourinary Medical Oncology Program
Medical Director, Clinical Trials Office
NYU Perlmutter Cancer Center
New York, New York

Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Ownership Interest: GT Biopharma Inc.

Virginia F Borges, MD, MMSc
Professor of Medicine with Tenure
John C and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program and
Young Women’s Breast Cancer Translational Program
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreement: Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Pfizer Inc, Seagen Inc.

Harold J Burstein, MD, PhD
Institute Physician, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

No relevant conflicts of interest to disclose.

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, Eisai Inc, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Hinova Pharmaceuticals Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Myovant Sciences, Pfizer Inc, PropellaTherapeutics Inc, TavantaTherapeutics; Contracted Research: Arvinas, Exelixis Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Hinova Pharmaceuticals Inc.

Justin F Gainor, MD
Director, Center for Thoracic Cancers at Massachusetts General Hospital
Director of Targeted Immunotherapy in the Henri and BelindaTermeer Center for Targeted Therapies
Associate Professor of Medicine at Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Oncology, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals.

J Randolph Hecht, MD
Professor of Clinical Medicine
Director, UCLA GI Oncology Program
Carol and Saul Rosenzweig Chair in Cancer Therapies Development
Santa Monica, California

Advisory Committee: Actym Therapeutics, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Mirati Therapeutics, Rafael Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Merck, Mirati Therapeutics, Tesaro, A GSK Company.

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Hospira Inc, Jazz Pharmaceuticals Inc, Merck, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Inovio Pharmaceuticals Inc, Lilly, Mirati Therapeutics, Takeda Oncology, Trizell; Data and Safety Monitoring Board/Committee: Lilly, Oncocyte.

Krishnansu S Tewari, MD
Professor and Division Director
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California

Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company.

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
Co-Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Amgen Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Exact Sciences, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Merck, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.

Release date: July 2021
Expiration date: July 2022